摘要: Resume La survenue de thromboembolies veineuses (TE) est frequente au cours des cancers bronchiques. Elles sont favorisees par la stase veineuse, l’hypercoagulabilite avec secretion tumeur facteurs procagulants et les lesions vasculaires induites chimiotherapies catheters centraux. Les heparines bas poids moleculaire (HBPM) SC ont remplace le traitement en aigu l’heparine non fractionnee IV. Un prolonge HBPM recommande pour eviter recidives. Une prevention doit etre systematique cas chirurgie ou d’hospitalisation. Il semble que ait, outre ses proprietes anticoagulantes, antineoplasiques effet benefique sur survie.
sci-hub.se 参考文章(20)
M. Monreal, L. Zacharski, J. A. Jimenez, J. Roncales, B. Vilaseca, Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. Journal of Thrombosis and Haemostasis. ,vol. 2, pp. 1311- 1315 ,(2004) , 10.1111/J.1538-7836.2004.00853.X
Agnes YY Lee, Mark N Levine, Ross I Baker, Chris Bowden, Ajay K Kakkar, Martin Prins, Frederick R Rickles, Jim A Julian, Susan Haley, Michael J Kovacs, Michael Gent, None, Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer New England Journal of Medicine. ,vol. 349, pp. 146- 153 ,(2003) , 10.1056/NEJMOA025313
Dominique Musset, Florence Parent, Guy Meyer, Sophie Maître, Philippe Girard, Christophe Leroyer, Marie-Pierre Revel, Marie-France Carette, Marcel Laurent, Bernard Charbonnier, François Laurent, Hervé Mal, Michel Nonent, Rémi Lancar, Philippe Grenier, Gerald Simonneau, Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentre outcome study The Lancet. ,vol. 360, pp. 1914- 1920 ,(2002) , 10.1016/S0140-6736(02)11914-3
Bernard Lebeau, Claude Chastang, Jeanne-Marie Brechot, Frédérique Capron, Berteand Dautzenberg, Corinne Delaisements, Michel Mornet, Janine Brun, Jean-Paul Hurdebourcq, Etienne Lemarie, Subcutaneous Heparin Treatment Increases Survival in Small Cell Lung Cancer Cancer. ,vol. 74, pp. 38- 45 ,(1994) , 10.1002/1097-0142(19940701)74:1<38::AID-CNCR2820740108>3.0.CO;2-E
Isabelle Gouin-Thibault, Meyer Samama, Laboratory diagnosis of the thrombophilic state in cancer patients. Seminars in Thrombosis and Hemostasis. ,vol. 25, pp. 167- 172 ,(1999) , 10.1055/S-2007-994918
John A. Heit, Marc D. Silverstein, David N. Mohr, Tanya M. Petterson, W. Michael O'Fallon, L. Joseph Melton, Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. JAMA Internal Medicine. ,vol. 159, pp. 445- 453 ,(1999) , 10.1001/ARCHINTE.159.5.445
William H Geerts, Graham F Pineo, John A Heit, David Bergqvist, Michael R Lassen, Clifford W Colwell, Joel G Ray, None, Prevention of Venous Thromboembolism : The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest. ,vol. 126, pp. 338- ,(2004) , 10.1378/CHEST.126.3_SUPPL.338S
P. Mismetti, S. Laporte, J.-Y. Darmon, A. Buchmüller, H. Decousus, Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. British Journal of Surgery. ,vol. 88, pp. 913- 930 ,(2002) , 10.1046/J.0007-1323.2001.01800.X
David Bergqvist, Giancarlo Agnelli, Alexander T. Cohen, Amiram Eldor, Paul E. Nilsson, Anne Le Moigne-Amrani, Flavia Dietrich-Neto, Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. The New England Journal of Medicine. ,vol. 346, pp. 975- 980 ,(2002) , 10.1056/NEJMOA012385
Hyman Engelberg, Actions of heparin that may affect the malignant process Cancer. ,vol. 85, pp. 257- 272 ,(1999) , 10.1002/(SICI)1097-0142(19990115)85:2<257::AID-CNCR1>3.0.CO;2-2